CompletedNCT01284517
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Medication studyAges 18–75Multiple countriesBipolarity
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Costa Mesa and 74 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 356
- Sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, Colombia, ...
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT01284517
- Official title
Show the full official title
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Costa Mesa, United States · Riverside, United States · San Diego, United States
61 more locations
- Santa Ana, United States
- Torrance, United States
- Highlands Ranch, United States
- Kissimmee, United States
- Orlando, United States
- Roswell, United States
- Smyrna, United States
- Flowood, United States
- New York, United States
- Raleigh, United States
- Portland, United States
- Allentown, United States
- Memphis, United States
- Dallas, United States
- Houston, United States
- Seattle, United States
- Edmonton, Canada
- Kelowna, Canada
- Gatineau, Canada
- Montreal, Canada
- Barranquilla, Colombia
- Bogotá, Colombia
- Cali, Colombia
- Brno-mesto, Czechia
- Olomouc, Czechia
- Prague, Czechia
- Visakhapatnam, India
- Kanchanpalli, India
- Vadodara, India
- Bangalore, India
- Mangalore, India
- Pune, India
- Wardha, India
- Jaipur, India
- Kanpur, India
- Lucknow, India
- Hachioji-shi, Japan
- Ichikawa, Japan
- Kanzaki-gun, Japan
- Kodaira-shi, Japan
- Sakaishi, Japan
- Takatsuki, Japan
- Kaunas, Lithuania
- Šilutė, Lithuania
- Vilnius, Lithuania
- Lima, Peru
- Bardejov, Slovakia
- Bojnice, Slovakia
- Bratislava, Slovakia
- Liptovský Mikuláš, Slovakia
- Rimavská Sobota, Slovakia
- Rožňava, Slovakia
- Trenčín, Slovakia
- Kherson, Ukraine
- Dnipropetrovsk, Ukraine
- Kharkiv, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Ternopil, Ukraine
- Zaporizhzhya, Ukraine
- Czechia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Lurasidone and Placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
